TLR7/8 agonist 4 TFA 

TLR7/8 agonist 4 TFA (compound 41) is a potent TLR7/8 agonist. TLR7/8 agonist 4 TFA has anti-cancer activity^[1].

Tumor growth is invariably accompanied by the acquisition of mutations that facilitate escape from immune surveillance. Nevertheless, the process of tumorigenesis leads to the accumulation of mutated antigens-specifically, neoantigens-which, following ex vivo stimulation, are readily recognized by the host immune system. Consequently, delivering these neoantigens to activated dendritic cells via antibody-tumor immune complexes offers a means to overcome the immune system's state of "immune ignorance" toward the tumor. Indeed, the simultaneous delivery of tumor-binding antibodies and dendritic cell adjuvants via intratumoral injection has successfully induced potent anti-tumor immune responses. Thus, dendritic cell adjuvants-such as Toll-like receptor agonists-represent a key potential strategy in the fight against cancer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

438.45

C₂₀H₂₅F₃N₆O₂

2388520-34-9

O=C(O)C(F)(F)F.NC1=NC2=CC=C(N3CCNCC3)C=C2C4=C1NC(CCCC)=N4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shelley Erin ACKERMAN, et al. Macromolecule-supported tlr agonists. WO2020190762A1.